Advances in Clinical and Experimental Medicine
2006, vol. 15, nr 1, January-February, p. 11–16
Publication type: editorial article
Clinical Use of the Tumor Marker Tissue Polypeptide Specific Antigen in Gastrointestinal Cancer
Przydatność kliniczna swoistego polipeptydu tkankowego jako markera w raku żołądkowo−jelitowym
1 IDL Biotech AB, Bromma, Sweden
2 CanAg Diagnostics, Gothenburg, Sweden
TPS (tissue polypeptide specific antigen) is a well−documented tumor marker for epithelial malignancies. It measures an antigenic determinant associated with human cytokeratin 18, utilizing an epitope defined by the monoclonal antibody M3. TPS is a marker of tumor cell activity, rather than the more commonly used markers related to tumor burden. The main clinical value of TPS lies in early detection of recurrent disease and in rapid assessment of treatment efficacy. Decreasing TPS levels during therapy monitoring indicate response and in case of a fast decrease, a favorable prognosis is often indicated. Further, increasing TPS levels in patients with clinically stable disease or partial remission is a reliable indicator of progression with a considerable lead time. When tumor marker determinations are applied in a proper way in the appropriate situation, the biomarker results can assist the oncologist. TPS has been shown to be of value in gastrointestinal malignancies, the site of more cancers than any other body organ system as exemplified by colorectal, gastric and pancreatic cancers. In advanced colorectal cancer, TPS is a powerful parameter during post−surgical follow−up and in monitoring palliative treatment. TPS levels significantly correlate with clinical outcome and therapy response. TPS is associated with aggressive disease and provide also prognostic information in colorectal cancer. In pancreatic cancer, TPS is a valuable indicator of the malignant process, important as a highly discriminative marker for differential diagnosis of pancreatic carcinoma and chronic pancreatitis. Increased TPS levels are a powerful parameter that supports the identification and differentiation of the cancer patients with high sensitivity and specificity.
TPS, cytokeratin 18, gastrointestinal cancer, colorectal, pancreas, diagnosis, prognosis, monitoring
- Parry D, Steinert PM: Intermediate filaments: Molecular architecture, assembly, dynamics and polymorphism. Q Rev Biophys 1999, 32, 99–187.
- Kirfel J, Magin TM, Reichelt J: Keratins: a structural scaffold with emerging functions. Cell Mol Life Sci 2003, 60, 56–71.
- Strelkov SV, Herrman H, Aebi U: Molecular architecture of intermediate filaments. BioEssays 2003, 25, 243–251.
- Osborn M, Weber K: Intermediate filaments: Cell−type specific markers in the differentiation and pathology. Cell 1982, 31, 303–306.
- Fuchs E, Weber K: Intermediate filaments, Structure, dynamics, function and disease. Ann Rev Biochem 1994, 63, 345–382.
- Moll R, Franke WW, Schiller DL, Geiger B, Krepler R: The catalog of human cytokeratins: Patterns of expression in normal epithelia, tumors and cultured cells. Cell 1982, 31, 11–24.
- Hatzfeld M, Franke WW: Pair formation and promiscuity of cytokeratins: Formation in vitro of heterotypic complexes and intermediate−sized filaments by homologous and heterologous recombinations of purified polypeptides. J Cell Biol 1985, 101, 1826–1841.
- Coulombe PA, Omary MB: “Hard” and “soft” principles defining the structure, function and regulation of keratin intermediate filaments. Curr Opin Cell Biol 2002, 14, 110–122.
- Lane EB, Alexander CM: Use of keratin antibodies in tumor diagnosis. Cancer Biol 1990, 1, 2707–2714.
- Chu PG, Weiss LM: Keratin expression in human tissues and neoplasms. Histopathology 2002, 40, 403–439.
- Rydlander L, Ziegler E, Bergman T et al.: Molecular characterization of a tissue−polypeptide−specific−antigen epitope and its relationship to human cytokeratin 18. Eur J Biochem 1996, 241, 309–314.
- Viktorsson K, Lewensohn R, Zhivotovsky B: Apoptotic pathways and therapy resistance in human malignancies. Adv Cancer Res 2005, 94, 143–196.
- Petak I, Houghton JA: Shared pathways: Death receptors and cytotoxic drugs in cancer therapy. Path Oncol Res 2001, 7, 95–106.
- Ku NO, Omary MB: Effect of mutation and phosphorylation of type I keratins on their caspase−mediated degradation. J Biol Chem 2001, 276, 26792–26798.
- Caulin C, Salvesen GS, Oshima RG: Caspase cleavage of keratin 18 and reorganization of intermediate filaments during epithelial cell apoptosis. J Biol Chem 1997, 138, 1379–1394.
- Sheard MA, Vojtesek B, Simickova, Valik D: Release of cytokeratin−18 and −19 fragments (TPS and CYFRA 21–1) into the extracellular space during apoptosis. J Cell Biochem 2002, 85, 670–677.
- Schutte et al.: Keratin 8/18 breakdown and reorganization during apoptosis: Exp Cell Res 2004, 297, 11–26.
- Barak V, Goike H, Panaretakis KW, Einarsson R: Clinical utility of cytokeratins as tumor markers. Clin Biochem 2004, 37, 529–540.
- Bonfrer JMG, Goenveld EM, Korse CM, Van Dalen A, Oomen LCJM, Ivanyi D: Monoclonal antibody M3 used in tissue polypeptide−specific antigen assay for the quantification of tissue polypeptide antigen recognizes keratin 18. Tumor Biol 1994, 15, 210–222.
- Lindman H, Jansson T, Arnberg H, Bergh J, Einarsson R: Serum markers TPS, TPA and CA 15–3 as monitors of chemotherapy in patients with metastatic breast cancer. J Tumor Marker Oncol 2000, 15, 177–186.
- Einarsson R, Barak V: TPS: A cytokeratin serum tumor marker for effective therapy control of cancer patients with focus on breast cancer. J Clin Ligand Assays 1999, 22, 348–351.
- Van Dalen A, Heering KJ, Barak V et al.: Treatment response in metastatic breast cancer: a multicenter study comparing UICC criteria and tumor marker changes. Breast 1996, 5, 82–88.
- Van Dalen A, Barak V, Cremaschi A et al.: The prognostic significance of increasing marker levels in metastatic breast cancer patients with clinically complete remission, partial remission or stable disease. A multicenter study. Int J Biol Markers 1998, 13, 10–15.
- Kramer G, Steiner G, Madersbacher S, Stulnig T, Lang T, Marberger M: Serial tissue polypeptide specific antigen in the follow−up of hormone treated carcinoma of the prostate. J Urol 1997, 158, 1446–1451.
- Polito M, Minardi D, Recchioni A, Giannulis L, De Sio G, Muzzonigro G: Serum markers for monitoring of prostatic carcinoma. Prostate 1997, 33, 208–216.
- Kil PJ, Goldschmidt HM, Wieggers BJ et al.: Tissue Polypeptide Specific antigen (TPS) determination before and during Intermittent Maximal Androgen Blockade in patients with prostatic carcinoma. Eur Urol 2003, 43, 31–38.
- Van Dalen A, Favier, Burges A et al.: Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients. Gynecol Oncol 2000, 79, 444–450.
- Glimelius B, Hoffman K, Einarsson R, Påhlman L, Graf W: Monitoring palliative chemotherapy in advanced gastrointestinal cancer using serial tissue polypeptide specific antigen (TPS) measurements. Acta Oncol 1996, 35, 141–148.
- Berglund Å, Molin D, Larsson A, Einarsson R, Glimelius B: Tumor markers as early predictors of response to chemotherapy in advanced colorectal carcinoma. Ann Oncol 2002, 13, 1430–1437.
- Nicolini A, Caciagli M, Zampieri F et al.: Usefulness of CEA, TPA, GICA, CA 72.4, and CA 195 in the diagnosis of primary colorectal cancer and its relapse. Cancer Detect Prev 1995, 19, 183–195.
- Carpelan−Holmstrom M, Haglund C, Lundin J, Alfthan H, Stenman UH, Roberts PJ: Independent prognostic value of preoperative serum markers CA242, specific tissue polypeptide antigen and human chronic gonadotrophin beta, but not of carcinoembryonic antigen or tissue polypeptide antigen in colorectal cancer. Br J Cancer 1996, 74, 925–929.
- Von Kleist S, Hesse Y, Kananeeh H: Comparative evaluation of four tumor markers, CA 242, CA 19/9, TPA and CEA in carcinomas of the colon. Anticancer Res 1996, 16, 2325–2331.
- Duffy, MJ: CA 19−9 as a marker for gastrointestinal cancers: a review. Ann Clin Biochem 1998, 35, 364–370.
- Ślesak B, Harłozińska−Szmyrka A, Knast W, Sedlaczek P, van Dalen A, Einarsson R: Tissue polypeptide specific antigen (TPS), a marker for differentiation between pancreatic carcinoma and chronic pancreatitis. Cancer 2000, 89, 83–88.
- Ślesak B, Harłozińska−Szmyrka A, Knast W, Sedlaczek P, Einarsson R, van Dalen A: TPS and CA 19−9 measurements in the follow−up of patients with pancreatic cancer and chronic pancreatitis. Int J Biol Markers 2004, 19, 115–119.